`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`MYLAN INSTITUTIONAL LLC and PFIZER INC.,
`Petitioners,
`
`v.
`
`NOVO NORDISK A/S,
`
`Patent Owner.
`
`
`Case No. IPR2020-003241
`U.S. Patent No. 8,114,833
`
`DECLARATION OF LARA J. DUEPPEN
`
`
`
`
`
`1
`IPR2020-01252 has been joined with this proceeding.
`
`
`
`MYLAN INST. EXHIBIT 1133 PAGE 1
`
`MYLAN INST. EXHIBIT 1133 PAGE 1
`
`
`
`I, Lara J. Dueppen, declare as follows:
`
`1.
`
`I am an attorney and partner at Perkins Coie LLP, and counsel for
`
`Petitioner Mylan Institutional LLC ("Mylan" or "Petitioner") in connection with
`
`the above-captioned inter partes review ("IPR").
`
`2.
`
`I am over the age of eighteen and otherwise competent to make this
`
`Declaration. I have personal knowledge of the facts set forth in this Declaration
`
`and am competent to testify to the same.
`
`3.
`
`Exhibit 1131 is a true and correct copy of an email that I received
`
`from
`
`the Patent Trial
`
`and Appeal Board End
`
`to End System
`
`(PTABE2E_System@uspto.gov) on March 5, 2021 (“Motion Filed Notice”),
`
`notifying the parties that Petitioners’ Motion to Exclude Evidence (Document No.
`
`54) was filed in IPR2020-00324. The email was also addressed to others, including
`
`Jeffrey
`
`Oelke
`
`(joelke@fenwick.com),
`
`Laura
`
`T.
`
`Moran
`
`(laura.moran@fenwick.com), and Ryan P. Johnson (ryan.johnson@fenwick.com),
`
`counsel for Patent Owner Novo Nordisk A/S.
`
`4.
`
`Exhibit 1132 is a true and correct copy of an email that I received
`
`from
`
`the Patent Trial
`
`and Appeal Board End
`
`to End System
`
`(PTABE2E_System@uspto.gov) on March 5, 2021 (“Document Filing Notice”),
`
`notifying the parties that Petitioners’ Motion to Exclude Evidence (Document No.
`
`54) was filed in IPR2020-00324. The email was also addressed to others, including
`
`2
`
`MYLAN INST. EXHIBIT 1133 PAGE 2
`
`MYLAN INST. EXHIBIT 1133 PAGE 2
`
`
`
`Jeffrey
`
`Oelke
`
`(joelke@fenwick.com),
`
`Laura
`
`T.
`
`Moran
`
`(laura.moran@fenwick.com), and Ryan P. Johnson (ryan.johnson@fenwick.com),
`
`counsel for Patent Owner Novo Nordisk A/S.
`
`
`
`March 19, 2021
`
`
`
`
`Respectfully submitted,
`
`/s/ Lara J. Dueppen
`Lara J. Dueppen
`
`3
`
`MYLAN INST. EXHIBIT 1133 PAGE 3
`
`MYLAN INST. EXHIBIT 1133 PAGE 3
`
`